Durable improvement of renal function after perindopril withdrawal in lyon hypertensive rats

Journal of Cardiovascular Pharmacology

Volumn 57, Issue 2, 2011, Pages 240-245

  Naelten, Gaëlle ^a   Liu, Kiao Ling ^a   Lo, Ming ^a  

^a UNIVERSITÉ LYON 1   (France)

Author keywords

angiotensin converting enzyme inhibition; blood pressure; genetic hypertension; pressure natriuresis; salt load

Indexed keywords

HYDRALAZINE; HYDROCHLOROTHIAZIDE; PERINDOPRIL; RESERPINE;

ANIMAL EXPERIMENT; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; BLOOD PRESSURE MEASUREMENT; BODY WEIGHT; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG DOSE COMPARISON; HEART RATE; HYPERTENSION; KIDNEY FUNCTION; MALE; MONOTHERAPY; NATRIURESIS; NONHUMAN; ORGAN WEIGHT; PRIORITY JOURNAL; PROTEINURIA; RAT; RENAL PROTECTION; SALT LOADING; SYSTOLIC BLOOD PRESSURE;

ANIMALS; BLOOD PRESSURE; HYPERTENSION; KIDNEY; KIDNEY FUNCTION TESTS; MALE; PERINDOPRIL; RANDOM ALLOCATION; RATS;

EID: 79951556670     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/FJC.0b013e318204bb7b     Document Type: Article

References (34)

1. Bianchi G, Fox U, Di Francesco GF, et al. Blood pressure changes produced by kidney cross-transplantation between spontaneously hypertensive rats and normotensive rats. Clin Sci Mol Med. 1974;47:435-448.
2. Curtis JJ, Luke RG, Dustan HP, et al. Remission of essential hypertension after renal transplantation. N Engl J Med. 1983;309:1009-1015. (Pubitemid 13014770)
3. Hall JE, Guyton AC, Brands MW. Pressure-volume regulation in hypertension. Kidney Int. 1996;49(Suppl 55):S35-S41.
4. Roman RJ. Altered pressure-natriuresis relationship in young spontaneously hypertensive rats. Hypertension. 1987;9:130-136.
5. Mulvany MJ. Small artery remodeling and significance in the development of hypertension. News Physiol Sci. 2002;17:105-109.
6. Guyton AC. Long-term arterial pressure control: an analysis from animal experiments and computer and graphic models. Am J Physiol. 1990;259: R865-R877. (Pubitemid 20387146)
7. Hall JE. The kidney, hypertension, and obesity. Hypertension. 2003;41: 625-633. (Pubitemid 36314565)
8. Dahlöf B, Devereux RB, Kjeldsen SE, et al; LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:995-1003. (Pubitemid 34286536)
9. Crowley SD, Gurley SB, Herrera MJ, et al. Angiotensin II causes hypertension and cardiac hypertrophy through its receptors in the kidney. Proc Natl Acad Sci U S A. 2006;103:17985-17990. (Pubitemid 44852272)
10. Vincent M, Boussäiri EH, Cartier R, et al. High blood pressure and metabolic disorders are associated in the Lyon hypertensive rat. J Hypertens. 1993;11:1179-1185. (Pubitemid 23330074)
11. Liu KL, Sassard J, Benzoni D. In the Lyon hypertensive rat, renal function alterations are angiotensin II dependent. Am J Physiol. 1996;271: R346-R351.
12. Florin M, Lo M, Liu KL, et al. Salt sensitivity in genetically hypertensive rats of the Lyon strain. Kidney Int. 2001;59:1865-1872. (Pubitemid 32336802)
13. Bertram D, Blanc-Brunat N, Sassard J, et al. Differential evolution of blood pressure and renal lesions after renin-angiotensin system blockade in Lyon hypertensive rats. Am J Physiol. 2002;283:R1041-R1045. (Pubitemid 35216977)
14. Miao CY, Liu KL, Benzoni D, et al. Acute pressure-natriuresis function shows early impairment in Lyon hypertensive rats. J Hypertens. 2005;23: 1225-1231. (Pubitemid 40862727)
15. Lantelme P, Lo M, Luttenauer L, et al. Pivotal role of the renin-angiotensin system in Lyon hypertensive rats. Am J Physiol. 1997;273:R1793-R1799. (Pubitemid 27518134)
16. Naelten G, Liu KL, Chapuis B, et al. Persistent effects on blood pressure and renal function of perindopril alone or combined with losartan in Lyon hypertensive rats. Am J Hypertens. 2005;18:699-706. (Pubitemid 40692439)
17. Kimura G, Saito F, Kojima S, et al. Renal function curve in patients with secondary forms of hypertension. Hypertension. 1987;10:11-15. (Pubitemid 17104006)
18. Rocchini AP, Key J, Bondie D, et al. The effect of weight loss on the sensitivity of blood pressure to sodium in obese adolescents. N Engl J Med. 1989;321:580-585. (Pubitemid 19212870)
19. Bennett MA, Hillier C, Thurston H. Endothelium-dependent relaxation in resistance arteries from spontaneously hypertensive rats: effect of long-term treatment with perindopril, quinapril, hydralazine or amlodipine. J Hypertens. 1996;14:389-397. (Pubitemid 26137637)
20. Paull JR, Widdop RE. Persistent cardiovascular effects of chronic renin-angiotensin system inhibition following withdrawal in adult spontaneously hypertensive rats. J Hypertens. 2001;19:1393-1402. (Pubitemid 32730456)
21. Christensen KL, Jespersen LT, Mulvany MJ. Development of blood pressure in spontaneously hypertensive rats after withdrawal of long-term treatment related to vascular structure. J Hypertens. 1989;7:83-90. (Pubitemid 19073982)
22. Roman RJ, Cowley AW Jr. Characterization of a new model for the study of pressure-natriuresis in the rat. Am J Physiol. 1986;248:F190-F198.
23. Dukacz SAW, Adams MA, Kline RL. Short- and long-term enalapril affect renal medullary hemodynamics in the SHR. Am J Physiol. 1999; 276:R10-R16. (Pubitemid 29061684)
24. Smallegange C, Kline RL, Adams MA. Transplantation of enalapril-treated kidneys confers persistent lowering of arterial pressure in SHR. Hypertension. 2003;42:932-936. (Pubitemid 37413733)
25. Dukacz SA, Feng MG, Yang LF, et al. Abnormal renal medullary response to angiotensin II in SHR is corrected by long-term enalapril treatment. Am J Physiol. 2001;280:R1076-R1084.
26. De Zeeuw D. Albuminuria, not only a cardiovascular/renal risk marker, but also a target for treatment. Kidney Int. 2004;92:S2-S6.
27. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 1997; 349: 1857-1863.
28. Viberti G, Wheeldon NM; MicroAlbuminuria Reduction With VALsartan (MARVAL) Study Investigators. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation. 2002;106:672-678. (Pubitemid 34851925)
29. Andersen S, Bröchner-Mortensen J, Parving HH; Irbesartan in Patients With Type 2 Diabetes and Microalbuminuria Study Group. Kidney function during and after withdrawal of long-term irbesartan treatment in patients with type 2 diabetes and microalbuminuria. Diabetes Care. 2003;26:3296-3302. (Pubitemid 37466890)
30. Egido J. Vasoactive hormones and renal sclerosis. Kidney Int. 1996;49: 578-597. (Pubitemid 26051838)
31. Attia DM, Feron O, Goldschmeding R, et al. Hypercholesterolemia in rats induces podocyte stress and decreases renal cortical nitric oxide synthesis via an angiotensin II type 1 receptor-sensitive mechanism. J Am Soc Nephrol. 2004;15:949-957. (Pubitemid 38375314)
32. Emonnot L, Cohen R, Lo M. Renal and metabolic disorders depend on the renin-angiotensin system in Lyon hypertensive rats associated with diabetes. Am J Hypertens. 2008;21:657-662. (Pubitemid 351733364)
33. Campbell DJ, Kladis A, Duncan AM. Effects of converting enzyme inhibitors on angiotensin and bradykinin peptides. Hypertension. 1994; 23:439-449. (Pubitemid 24102039)
34. Allard J, Buléon M, Cellier E, et al. ACE inhibitor reduces growth factor receptor expression and signaling but also albuminuria through B2-kinin glomerular receptor activation in diabetic rats. Am J Physiol. 2007;293: F1083-F1092. (Pubitemid 47583940)